V3: Vancouver-Victoria Valacyclovir Trial for Early Psychosis
- Sponsor
- University of British Columbia
- Study ID
- NCT00175513
- Phase
- PHASE2
- Status
- Completed
Conditions
- Psychosis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- Valacyclovir (Valtrex) — DRUG
Study Details
This is an 18 week (2 weeks run-in, 16 weeks double blind) trial, to determine if an antiviral drug, valacyclovir (Valtrex) is helpful in treating the symptoms of psychosis, a form of a mental disorder.
Key Dates
- Start date
- Sep 30, 2005
- Status verified
- Apr 2011
- Primary completion
- Sep 30, 2009
- Completion
- Sep 30, 2009
Study Design
- Enrollment
- 100 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Related Studies
- Toward a Computationally-Informed, Personalized Treatment for HallucinationsEARLY_PHASE1 · Recruiting · Yale University · New Haven, Connecticut
- Normobaric Oxygen Therapy for Individuals With First-Episode PsychosisRecruiting · Nicholas Breitborde · Columbus, Ohio
- Neurobehavioral Mechanisms of Social Isolation and Loneliness in Serious Mental IllnessRecruiting · Massachusetts General Hospital · Charlestown, Massachusetts
- Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis RiskRecruiting · Northwell Health · Glen Oaks, New York